Cooley Advises Alder Biopharmaceuticals on Initial Public Offering

Seattle – May 14, 2014 – Cooley LLP announced today that it advised Alder Biopharmaceuticals, Inc. on its $80 million initial public offering. Alder is a Washington-based clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder is currently developing two lead product candidates: ALD403, an investigational monoclonal antibody for migraine, and Clazakizumab, an investigational monoclonal antibody for rheumatoid arthritis and other autoimmune indications, in collaboration with Bristol-Myers Squibb.  The company now trades on the NASDAQ Global Stock Market under the symbol "ALDR."

The Cooley corporate and securities team advising Alder was led by partners Sonya Erickson and John McKenna and included associates Julia Conway, Alan Hambelton, Michael Pirog and Yuri Weigel. Critical support for the offering was provided by partners Renee Deming and Amy Wood and special counsel Jeannie Leahy (compensation & benefits); partners Natasha Leskovsek and Marya Postner (regulatory & licensing); and partners Mark Windfeld-Hansen and Susan Philpot (tax).

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.